8-K: NeuroPace Stockholders Re-Elect Directors and Ratify Auditor at 2025 Annual Meeting

NeuroPace, Inc. announced the successful election of Class I directors Joel Becker and Frank Fischer, and the ratification of PricewaterhouseCoopers LLP as its independent auditor for 2025, following its virtual Annual Meeting of Stockholders on June 6, 2025.

Summary

• NeuroPace, Inc. held its 2025 Annual Meeting of Stockholders virtually via live webcast on June 6, 2025.
• Stockholders elected Joel Becker and Frank Fischer as Class I director nominees to serve until the 2028 Annual Meeting of Stockholders.
• Joel Becker received 19,735,539 votes For and 120,448 votes Withhold, with 7,730,356 Broker Non-Votes.
• Frank Fischer received 14,717,455 votes For and 5,138,532 votes Withhold, with 7,730,356 Broker Non-Votes.
• Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The ratification of PricewaterhouseCoopers LLP received 27,489,833 votes For, 90,789 votes Against, and 5,721 votes Abstain.

Sentiment

Score: 7

Explanation: The document reports the successful completion of routine corporate governance matters, including the election of directors and ratification of the auditor, with strong shareholder support for all proposals. This indicates stability and adherence to standard corporate practices, which is generally positive for investor confidence.

Positives

• Successful election of both nominated Class I directors, ensuring continuity in corporate governance.
• Overwhelming ratification of PricewaterhouseCoopers LLP as the independent auditor, indicating strong shareholder confidence in the company's financial oversight.

Future Outlook

The elected Class I directors, Joel Becker and Frank Fischer, are expected to hold office until NeuroPace's 2028 Annual Meeting of Stockholders. PricewaterhouseCoopers LLP has been ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized." (Signed by Rebecca Kuhn, Chief Financial Officer and Vice President, Finance and Administration)

Industry Context

This filing pertains to routine corporate governance matters, specifically the outcomes of an annual stockholder meeting. It does not provide information related to broader industry trends or competitive landscape within the medical device or neuromodulation sector.

Comparison to Industry Standards

• The successful election of directors and ratification of auditors are standard corporate governance practices. The voting results, with a clear majority for the proposals, align with typical outcomes for well-managed public companies. No specific comparable companies or projects are mentioned in the document to allow for a detailed comparison of results.

Corporate Governance

Stakeholder Impact

• Shareholders: Voted on key corporate governance matters, including director elections and auditor ratification, directly influencing the company's oversight and accountability.

Next Steps

• The elected Class I directors will hold office until the 2028 Annual Meeting of Stockholders.
• PricewaterhouseCoopers LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

NeuroPace, NPCE, Annual Meeting, Stockholders, Director Election, Auditor Ratification, Corporate Governance, SEC Filing, 8-K, PricewaterhouseCoopers LLP